Stocky turns companies like Dyne Therapeutics, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Dyne Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings show how the company is performing and whether it's making progress toward profitability.
The detailed 10-Q reveals balance sheet, cash, debts, and research spending that investors need to track financial health.
A prospectus update means the company is preparing to raise money by selling stock or debt to investors.
The company is raising capital through a public stock sale, which dilutes existing shareholders but funds operations.
Formal registration allows the company to sell stocks, bonds and other securities to raise needed cash.
Priority review of z-rostudirsen for muscular dystrophy means the drug is one step closer to market and potential revenue.
New board members bring experience and oversight; this one received stock options worth incentivizing his leadership.
Stocky reads Dyne Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Dyne Therapeutics, Inc.'s most recent tracked filing was a 8-K on 29 Jul 2026: Dyne reports second-quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.